Iron polysaccharide

Iron-Dextran is an intravenous iron delivery preparation that is often compared with other iron preparations such as iron gluconate, iron sucrose and ferric carboxymaltose for safety, efficacy and indication.

BD supplies more than 400 different BD Difcoâ„¢ and BD BBLâ„¢ brand media formulations and ingredients in dehydrated form for the convenience of the laboratorian and bioprocessing specialist. Used for the differentiation of members of the

LACTOFERRIN (LOW IRON)

Mouse anti Human Lipocalin-2 / NGAL Antibody, Monoclonal (J13), could be used for WB and so on. Application: WB: 0.5-2µg/mL Protein Function Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal

Mouse anti Human Lipocalin-2 / NGAL Antibody, Monoclonal (J13), could be used for WB and so on. Application: WB: 0.5-2µg/mL Protein Function Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal

Mouse anti Human Lipocalin-2 / NGAL Antibody, Monoclonal (J13), could be used for WB and so on. Application: WB: 0.5-2µg/mL Protein Function Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal

Mouse anti Human Lipocalin-2 / NGAL Antibody, Monoclonal (J13), could be used for WB and so on. Application: WB: 0.5-2µg/mL Protein Function Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal

LY2787106 (anti-Hepcidin) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and

LY2787106 (anti-Hepcidin) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and

LY2787106 (anti-Hepcidin) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and

LY2787106 (anti-Hepcidin) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and

Ferosul, 5gr, Film Coated, Green Tablets, 100s, Compare to Feosol, NDC# 00904-7591-60